Skip to main
  1. Stocks
  2. Aclaris Therapeutics
  3. Forecast
ACRS

Aclaris Therapeutics (ACRS) Stock Forecast & Price Target

Aclaris Therapeutics (ACRS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 43%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Aclaris Therapeutics is viewed favorably because its ATI-052 Phase 1b data showed strong proof-of-concept in both atopic dermatitis and asthma, with rapid efficacy signals, no Grade 3 or 4 adverse events, no conjunctivitis, and a safety profile that supports broader development. The atopic dermatitis readout was especially compelling, including a 45% placebo-adjusted mean EASI improvement, 78% placebo-adjusted EASI-50, and 95% normalization of the lesional skin proteome by week 8, while management believes quarterly dosing may be achievable versus Dupixent’s twice-monthly regimen. Financially, the company strengthened its balance sheet with an underwritten offering expected to raise about $50M and extend runway well into 2029, supporting continued development of ATI-052 and the rest of the pipeline.

Bears say

Aclaris Therapeutics is viewed negatively because bosakitug’s Phase II ADMIRATION study in atopic dermatitis missed both primary and secondary endpoints, undermining confidence in the company’s TSLP strategy and suggesting that target engagement alone may not translate into meaningful clinical benefit. The setback also weakens the rationale for ATI-052 in AD, where the analyst lowered probability of success estimates to 20% in the U.S. and 15% in the EU, while acknowledging growing competitive and regulatory risks in eosinophilic esophagitis. With modzatinib’s top-line data not expected until 2H27 and ATI-052’s Phase IIb EoE trial only planned for 1Q27, the pipeline remains highly speculative and delayed.

Aclaris Therapeutics (ACRS) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 43% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclaris Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Aclaris Therapeutics (ACRS) Analyst Forecast & Price Prediction

Get the latest Aclaris Therapeutics (ACRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aclaris Therapeutics (ACRS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclaris Therapeutics (ACRS) Forecast

Analysts have given Aclaris Therapeutics (ACRS) a Buy based on their latest research and market trends.

According to 7 analysts, Aclaris Therapeutics (ACRS) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclaris Therapeutics (ACRS)


Aclaris Therapeutics (ACRS) Analyst Forecast & Price Prediction

Get the latest Aclaris Therapeutics (ACRS) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aclaris Therapeutics (ACRS)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ACRS stock data and trends